Decrease in Peripheral Blood Polymorphonuclear Leukocyte Chemotactic Index in Endometriosis: Role of Prostaglandin E2 Release

G G Garzetti, A Ciavattini, M Provinciali, M Amati, M Muzzioli, M Governa
Obstetrics and gynecology · 1998 · vol. 91(1) , pp. 25–29 · doi:10.1016/s0029-7844(97)00592-9 · PMID:9464715 · W3023023270
article OA: closed CC0 ⤵ 12 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Tamoxifen therapy in postmenopausal breast cancer patients alters insulin-like growth factor-1 and insulin-like growth factor-binding protein-1 expression in the endometrium, potentially contributing to its uterotropic effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

To determine whether modulation of insulin-like growth factor-1 and insulin-like growth factor-binding protein-1 expression underlies the uterotropic effects associated with tamoxifen therapy in postmenopausal breast cancer patients. Using immunohistochemical techniques, we analyzed 37 endometrial specimens from biopsies (n = 18) or hysterectomies (n = 19) for Ki-67, insulin-like growth factor-1, and insulin-like growth factor-binding protein-1 expression. Specifically, five secretory- and three prolif erativephase endometrial specimens were used as controls; 20 specimens (including two endometrial adenocarcinomas) were analyzed from postmenopausal breast cancer patients treated with tamoxifen (20 mg/day) for at least 6 months; and nine endometrial adenocarcinoma specimens from patients not treated with tamoxifen were studied. Intensity of immunostaining was quantified using digitized imaging techniques. Insulin-like growth factor-1 and insulin-like growth factor-1-binding protein-1 were found to be expressed in normal and neoplastic endometrium of all patients, regardless of tamoxifen treatment. However, insulinlike growth factor-1 expression varied cyclically in histologically normal endometrium, was reduced in undifferentiated endometrial tumors, and was upregulated in tamoxifen-treated specimens. Insulin-like growth factorbinding protein-1 immunostaining did not vary during the menstrual cycle, but it was reduced significantly in benign tamoxifen-exposed tissue and endometrial adenocarcinomas, regardless of degree of differentiation or tamoxifen exposure. No correlation was found between the expression of insulin-like growth factor-1 and insulin-like growth factor-binding protein-1 and the proliferative indices of the tissues examined. The expression of insulin-like growth factor-1 and insulin-like growth factor-binding protein-1 in the uterus supports an automne and/or paracrine role for these proteins in endometrial physiology. Although further studies are needed, our investigation suggests that altered expression of insulin-like growth factor-1 and insulin-like growth factor-binding protein-1 may contribute to the uterotropic effects of tamoxifen. Funding for the study was provided by the Department of Clinical Investigation, Walter Reed Army Medical Center, and the Research Administration, Uniformed Services University of the Health Sciences.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Chemotaxis, Leukocyte Cytotoxicity, Immunologic Dinoprostone Endometriosis Estradiol Killer Cells, Natural Adult Chemotaxis, Leukocyte Cytotoxicity, Immunologic Diagnostic Techniques and Procedures Dinoprostone Endometriosis Endometriosis Endometriosis Estradiol Female Humans Killer Cells, Natural Neutrophils Neutrophils

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Cited by (12)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:46.468712+00:00
License: CC0 · commercial use OK